Burkitt Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Burkitt lymphoma markets reached a value of US$ 996.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2,627.8 Million by 2034, exhibiting a growth rate (CAGR) of 9.22% during 2024-2034.
The Burkitt lymphoma market has been comprehensively analyzed in IMARC's new report titled "Burkitt Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Burkitt lymphoma refers to a type of non-Hodgkin lymphoma that is characterized by rapidly growing cancerous cells in the lymphatic system. Some of the common symptoms include swollen lymph nodes in the neck, armpit, or groin; fever; night sweats; weight loss; fatigue; abdominal pain or swelling, etc. In many cases, the cancer can affect other organs like the central nervous system or gastrointestinal tract, leading to additional symptoms, such as anemia, neurological problems, digestive issues, etc. The diagnosis of Burkitt lymphoma typically involves a combination of imaging procedures, blood tests, and a biopsy of an affected lymph node or other tissue. Various imaging studies, including CT scans and MRIs, can help identify the location and extent of the cancer, while blood tests may reveal abnormalities like anemia or elevated levels of lactate dehydrogenase (LDH). Additional tests, such as a bone marrow biopsy or lumbar puncture to look for cancer cells in the central nervous system, may be done to determine the subtype of Burkitt lymphoma and assess the extent of the disease.
The increasing incidences of genetic translocation, in which the MYC gene becomes overactive, thereby leading to uncontrolled cell growth and development of cancer, are primarily driving the Burkitt lymphoma market. In addition to this, the escalating utilization of stem cell transplantation in high-risk cases to help restore the immune system and prevent cancer recurrence, is further bolstering the market growth. Moreover, the widespread adoption of prophylactic CNS therapy, such as intrathecal chemotherapy or radiation therapy to the brain and spinal cord, for preventing or delaying CNS involvement is also creating a positive outlook for the Burkitt lymphoma market. Additionally, numerous key players are making extensive investments in developing reduced-intensity regimens that can achieve favorable outcomes with fewer side effects. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of molecular imaging techniques, such as positron emission tomography (PET) scans, since they can identify areas of disease that are not visible on conventional imaging, is expected to drive the Burkitt lymphoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Burkitt lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Burkitt lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Burkitt lymphoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Burkitt lymphoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Burkitt lymphoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Burkitt lymphoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Burkitt lymphoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Burkitt lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Burkitt lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Burkitt lymphoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of Burkitt lymphoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Burkitt lymphoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Burkitt lymphoma across the seven major markets?
What is the size of the Burkitt lymphoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Burkitt lymphoma?
What will be the growth rate of patients across the seven major markets?
Burkitt Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Burkitt lymphoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Burkitt lymphoma market?
What are the key regulatory events related to the Burkitt lymphoma market?
What is the structure of clinical trial landscape by status related to the Burkitt lymphoma market?
What is the structure of clinical trial landscape by phase related to the Burkitt lymphoma market?
What is the structure of clinical trial landscape by route of administration related to the Burkitt lymphoma market?
The Burkitt lymphoma market has been comprehensively analyzed in IMARC's new report titled "Burkitt Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Burkitt lymphoma refers to a type of non-Hodgkin lymphoma that is characterized by rapidly growing cancerous cells in the lymphatic system. Some of the common symptoms include swollen lymph nodes in the neck, armpit, or groin; fever; night sweats; weight loss; fatigue; abdominal pain or swelling, etc. In many cases, the cancer can affect other organs like the central nervous system or gastrointestinal tract, leading to additional symptoms, such as anemia, neurological problems, digestive issues, etc. The diagnosis of Burkitt lymphoma typically involves a combination of imaging procedures, blood tests, and a biopsy of an affected lymph node or other tissue. Various imaging studies, including CT scans and MRIs, can help identify the location and extent of the cancer, while blood tests may reveal abnormalities like anemia or elevated levels of lactate dehydrogenase (LDH). Additional tests, such as a bone marrow biopsy or lumbar puncture to look for cancer cells in the central nervous system, may be done to determine the subtype of Burkitt lymphoma and assess the extent of the disease.
The increasing incidences of genetic translocation, in which the MYC gene becomes overactive, thereby leading to uncontrolled cell growth and development of cancer, are primarily driving the Burkitt lymphoma market. In addition to this, the escalating utilization of stem cell transplantation in high-risk cases to help restore the immune system and prevent cancer recurrence, is further bolstering the market growth. Moreover, the widespread adoption of prophylactic CNS therapy, such as intrathecal chemotherapy or radiation therapy to the brain and spinal cord, for preventing or delaying CNS involvement is also creating a positive outlook for the Burkitt lymphoma market. Additionally, numerous key players are making extensive investments in developing reduced-intensity regimens that can achieve favorable outcomes with fewer side effects. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of molecular imaging techniques, such as positron emission tomography (PET) scans, since they can identify areas of disease that are not visible on conventional imaging, is expected to drive the Burkitt lymphoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Burkitt lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Burkitt lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Burkitt lymphoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Burkitt lymphoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Burkitt lymphoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Burkitt lymphoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Burkitt lymphoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Burkitt lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Burkitt lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Burkitt lymphoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of Burkitt lymphoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Burkitt lymphoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Burkitt lymphoma across the seven major markets?
What is the size of the Burkitt lymphoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Burkitt lymphoma?
What will be the growth rate of patients across the seven major markets?
Burkitt Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Burkitt lymphoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Burkitt lymphoma market?
What are the key regulatory events related to the Burkitt lymphoma market?
What is the structure of clinical trial landscape by status related to the Burkitt lymphoma market?
What is the structure of clinical trial landscape by phase related to the Burkitt lymphoma market?
What is the structure of clinical trial landscape by route of administration related to the Burkitt lymphoma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BURKITT LYMPHOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BURKITT LYMPHOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BURKITT LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 BURKITT LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BURKITT LYMPHOMA - UNMET NEEDS
10 BURKITT LYMPHOMA - KEY ENDPOINTS OF TREATMENT
11 BURKITT LYMPHOMA - MARKETED PRODUCTS
11.1 List of Burkitt Lymphoma Marketed Drugs Across the Top 7 Markets
11.1.1 Cyclophosphamide oral - Hikma Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rituxan (Rituximab) - Biogen Idec/Genentech
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BURKITT LYMPHOMA - PIPELINE DRUGS
12.1 List of Burkitt Lymphoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Brexucabtageneautoleucel - Kite Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Sepantronium Bromide - Cothera Bioscience
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ADCT402 - ADC Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BURKITT LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BURKITT LYMPHOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BURKITT LYMPHOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Burkitt Lymphoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Burkitt Lymphoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Burkitt Lymphoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Burkitt Lymphoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Burkitt Lymphoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Burkitt Lymphoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Burkitt Lymphoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Burkitt Lymphoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Burkitt Lymphoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Burkitt Lymphoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Burkitt Lymphoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Burkitt Lymphoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Burkitt Lymphoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Burkitt Lymphoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Burkitt Lymphoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Burkitt Lymphoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Burkitt Lymphoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Burkitt Lymphoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Burkitt Lymphoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Burkitt Lymphoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Burkitt Lymphoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Burkitt Lymphoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Burkitt Lymphoma - Access and Reimbursement Overview
16 BURKITT LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BURKITT LYMPHOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BURKITT LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BURKITT LYMPHOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BURKITT LYMPHOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BURKITT LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 BURKITT LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BURKITT LYMPHOMA - UNMET NEEDS
10 BURKITT LYMPHOMA - KEY ENDPOINTS OF TREATMENT
11 BURKITT LYMPHOMA - MARKETED PRODUCTS
11.1 List of Burkitt Lymphoma Marketed Drugs Across the Top 7 Markets
11.1.1 Cyclophosphamide oral - Hikma Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rituxan (Rituximab) - Biogen Idec/Genentech
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BURKITT LYMPHOMA - PIPELINE DRUGS
12.1 List of Burkitt Lymphoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Brexucabtageneautoleucel - Kite Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Sepantronium Bromide - Cothera Bioscience
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ADCT402 - ADC Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BURKITT LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BURKITT LYMPHOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BURKITT LYMPHOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Burkitt Lymphoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Burkitt Lymphoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Burkitt Lymphoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Burkitt Lymphoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Burkitt Lymphoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Burkitt Lymphoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Burkitt Lymphoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Burkitt Lymphoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Burkitt Lymphoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Burkitt Lymphoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Burkitt Lymphoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Burkitt Lymphoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Burkitt Lymphoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Burkitt Lymphoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Burkitt Lymphoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Burkitt Lymphoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Burkitt Lymphoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Burkitt Lymphoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Burkitt Lymphoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Burkitt Lymphoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Burkitt Lymphoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Burkitt Lymphoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Burkitt Lymphoma - Access and Reimbursement Overview
16 BURKITT LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BURKITT LYMPHOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BURKITT LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
